EP
CHRS icon

Essential Partners’s Coherus Oncology CHRS Stock Holding History

Essential Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12K Sell
803
-740
-48% -$1.21K ﹤0.01% 2191
2026
Q1 		$2.61K Buy
1,543
+892
+137% +$1.58K ﹤0.01% 1894
2025
Q4 		$924 Buy
651
+87
+15% +$127 ﹤0.01% 2054
2025
Q3 		$925 Buy
564
+100
+22% +$111 ﹤0.01% 2040
2025
Q2 		$339 Buy
+464
New +$401 ﹤0.01% 1807

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Essential Partners's CHRS Position: Q2 2026 in Review

Essential Partners reduced its Coherus Oncology (CHRS) stake by 48% in Q2 2026, selling an estimated $1.21K and leaving 803 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

Essential Partners first reported a position in CHRS in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.61K in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Essential Partners held 803 shares of Coherus Oncology worth $1.12K as of Q2 2026.
  • Essential Partners sold 740 Coherus Oncology shares in Q2 2026, an estimated $1.21K.
  • Coherus Oncology made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2191 holding.
  • Essential Partners first reported a position in Coherus Oncology in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Coherus Oncology position peaked at $2.61K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.